Case Study, CSM: Constitutional CNS

by

Constitutional CNS — Developmental Vulnerability and Autoimmune Vasculopathy

Laurel Fitzhugh — May 20, 2026 | Status: Draft — working document

Laurel Fitzhugh presents with a decades-long multi-system clinical picture that has been managed as a collection of separate diagnoses. The evidence, reviewed in full, points toward two converging constitutional factors — a developmentally established neurological vulnerability and an acquired autoimmune vasculopathy, possibly antiphospholipid syndrome — that have been operating on the same system simultaneously, each amplifying the consequences of the other. The neurological system is the territory where these factors converge, and damage to central autonomic regulatory capacity is the mechanism through which they have driven the severity and refractoriness of the entire clinical picture. The individual diagnoses are downstream expressions of upstream conditions. This document is a framework for understanding the constitutional picture on its own terms, for informing decisions at the margins, and for the record.

I. The Evidence Base

Arranged chronologically, the clinical picture reveals a single process expressing itself across multiple systems over decades rather than a series of independent conditions accumulating over time. The thread running through the chronological picture is a consistent pattern of neurological reactions across mechanistically unrelated drugs, systems, and time periods.

Early Adulthood — Neurological Vulnerability Before Diagnosis

The earliest hard data point for neurological vulnerability predates the RA diagnosis by at least eight years. Before 2008 — likely in the early-to-mid 2000s, possibly earlier during pregabalin’s trial period — pregabalin was prescribed for widespread pain that had been labeled fibromyalgia. The drug produced sudden loss of postural tone without dizziness, warning, or loss of consciousness — clinically consistent with pregabalin-induced negative myoclonus, a cortical inhibitory phenomenon distinct from standard pregabalin adverse effects in both character and severity. These episodes resolved within days of discontinuation. Negative myoclonus of this severity at therapeutic doses indicates a cortical system already operating with reduced reserve, responding to GABAergic modulation by crossing a threshold that a normally resilient nervous system would not approach.

The fibromyalgia diagnosis itself is suspect in retrospect. The tender point criteria that defined fibromyalgia in that era were not clearly met. The widespread pain, fatigue, and systemic symptoms present by around 2000 may have represented the early expression of an autoimmune process that could not yet be named — not a primary pain syndrome, but a system already under constitutional stress expressing itself through the channels available.

2008 — RA Diagnosis and the Methotrexate Signal

Seropositive RA was diagnosed in 2008, confirming autoimmune disease that had probably been active for years. Methotrexate was prescribed and taken for three to four weeks. Within that period, severe peripheral neuropathy developed alongside a psychiatric presentation that was entirely unprecedented: continuous uncontrollable crying throughout all waking hours, and suicidal ideation. The reaction began within days of the first dose. After discontinuation, both the neuropathy and the psychiatric symptoms resolved rapidly — the treating primary care physician was struck by the completeness of the recovery.

While depression, mood effects, and cognitive impairment are documented neuropsychiatric adverse effects of low-dose methotrexate — primarily through folate antagonism — the severity and character of this reaction substantially exceeded what low-dose oral methotrexate typically produces. The rapid and complete resolution after discontinuation suggests a threshold crossed within days of the first dose, rather than a standalone toxic effect accumulating over time. The neuropathy and the earlier pregabalin episodes form a pattern: the nervous system responding to pharmacological perturbation in ways that exceed what the drug alone explains.

2008–2018 — The Biologic Failure Pattern and Escalating CNS Stress

Four biologics failed over a decade. The failure pattern is notable not just for its completeness but for its character. Humira and Simponi produced no response of any kind — neither benefit nor any discernible effect, positive or negative. Tocilizumab and abatacept both produced neurological adverse effects as the primary reaction, requiring discontinuation. The distinction matters: two drugs produced nothing, two drugs produced neurological reactions. That split is not what you would expect from standard biologic failure in refractory RA.

This binary pattern — complete non-response or amplified reaction, with no middle ground — reflects a broader pharmacological phenotype that extends across drug classes and mechanisms throughout the clinical history. Medications either fail to engage the system entirely, or engage it with intensity and speed that substantially exceeds clinical expectations. A nervous system with reduced reserve responds this way: either the threshold is not reached, or crossing it produces a disproportionate effect.

Each drug that produced a neurological reaction was itself an additional CNS insult layered onto an already compromised system. The medication sensitivity pattern extends beyond the biologics — hydroxychloroquine produced an acute vestibular crisis of such severity that emergency services were called, with a presentation indistinguishable from major stroke and inability to stand; the damage did not fully reverse. Ibuprofen was permanently foreclosed following sensitization that included permanent partial voice change. The pattern across mechanistically unrelated drugs, spanning more than a decade and multiple pharmacological classes, is not a collection of individual drug sensitivities. It is a constitutionally compromised nervous system in which each additional pharmacological insult reduced the remaining reserve.

2016 — First Stroke and Baseline Vascular Imaging

The left temporal lobe acute ischemic infarct in June 2016 was preceded by a motor vehicle accident ten days prior. The embolic source was never identified after extensive workup including transesophageal echocardiography — TEE June 2017 found no cardioembolic substrates, no atrial septal defect or PFO, and a negative bubble study. A trauma-precipitated stroke in a patient with unidentified hypercoagulable state and chronic autoimmune vascular inflammation is mechanistically coherent — the trauma may have provided a triggering event for a vascular system already primed for thrombosis. Specialists discounted the trauma as a contributing factor; it is retained here as a mechanistic possibility rather than a clinical conclusion.

The MRI performed the same day documented the acute infarct and also noted — without emphasis — a few small scattered foci of increased signal intensity in deep and subcortical white matter tracts compatible with minor small vessel ischemic change. This is the first documented evidence of small vessel CNS disease, and it predates the stroke — it is described as compatible with chronic small vessel change, not acute. The microangiopathy was already present at the first available brain imaging.

The MRA performed the same day — the first cerebrovascular imaging ever obtained — established the constitutional vascular architecture in full: diminutive vertebrobasilar system, posterior circulation primarily supplied by an ectatic right persistent trigeminal artery, a 4mm right cavernous ICA aneurysm, and a probable 2mm left MCA branch aneurysm. No prior comparisons were available. This architecture was not acquired or progressive at this point — it was simply documented for the first time when the stroke brought it to clinical attention. The trigeminal artery was already ectatic at first imaging. The constitutional vascular developmental difference predates all documented pathology.

2017 — The Left Hand Signal and a Neurological Episode

Neuropsychological evaluation in June 2017, one year after the left temporal stroke, documented moderate left hand motor impairment. The evaluator flagged this finding explicitly as inconsistent with the left temporal stroke location. In retrospect, it suggests right hemisphere dysfunction that was already present and possibly progressive before the 2018 event.

Between the two strokes, a one-day episode of memory disturbance and repetitive thinking was noted. It was attributed at the time to statin side effects and led to medication discontinuation. In retrospect, in a patient with bilateral progressive small vessel disease between two cryptogenic strokes, a transient cognitive episode of this character warrants consideration as a possible minor vascular event.

2018 — Second Stroke and Imaging

In May 2018, an ER visit for headache prompted CT head — normal. Two months later, the right insular cortical CVA in July 2018 extended into the adjacent frontal operculum. The embolic source was again never identified. The attending cardiologist, reviewing the clinical picture, concluded that the stroke appeared potentially related to the growing right ICA aneurysm — an interpretation that points toward intrinsic vascular wall pathology rather than embolic mechanism.

MRI performed after the second stroke documented: “Chronic small vessel ischemic changes are mild in the juxtacortical and deep white matter of both cerebral hemispheres diffusely.” The bilateral distribution — both hemispheres — is critical. The left temporal stroke would not explain right hemisphere white matter changes, and the right insular stroke would not explain left hemisphere changes. Bilateral small vessel disease at the time of the second stroke is independent evidence of a diffuse process, not stroke-related damage.

CTA performed at the time of the second stroke documented the right cavernous ICA aneurysm now at 6mm — grown from 4mm at the 2016 baseline.

2022 — The Antiphospholipid Signal

In December 2022, antiphospholipid antibody testing ordered by primary care returned two elevated values: anticardiolipin IgM at 21 against a normal of less than 13, and beta-2 glycoprotein I IgM at 63 against a normal of less than 33. The remaining three antibodies in the panel were negative. Confirmatory testing, required by APS diagnostic criteria, was not ordered. The results were not communicated to Barrow neurology. In the context of two cryptogenic strokes and decades of unexplained thrombocytosis, these results represent an open diagnostic question.

The Aneurysm Progression

The right cavernous ICA aneurysm growth trajectory documents active vessel wall instability over years: 4mm at first imaging June 2016 → 6mm by July 2018 → approximately 1.2cm by March 2023 — nearly tripling in two dimensions over seven years. Pipeline embolization was performed May 2023; subsequent imaging confirms no residual aneurysm filling and stable stent. The aneurysm grew substantially during the period of worst inflammatory activity and least treatment.

The left MCA branch aneurysm, probable at 2mm on first imaging in 2016, has remained stable across nine years of surveillance. The trigeminal artery itself carries a 2mm saccular outpouching directed dorsally, abutting the ventral surface of the pons — present since at least 2018, stable across all subsequent imaging.

Additional vascular variants documented across the series: prominent infundibulum at the left posterior communicating artery origin, complex anterior communicating artery configuration. The vascular developmental abnormality is distributed, not focal.

The Small Vessel Disease Progression

The small vessel CNS disease is now documented across four imaging time points spanning nine years:

  • June 2016 — present at first stroke imaging, predating the acute event; “few small scattered foci in deep and subcortical white matter”
  • July 2018 — bilateral at time of second stroke; “mild in juxtacortical and deep white matter of both cerebral hemispheres diffusely” — bilateral distribution independent of either stroke location
  • May 2024 — more extensive, specifically localized to posterior right frontal region adjacent to motor and autonomic pathways
  • July 2025 — confirmed slightly increased from 2018

The small vessel disease predates both strokes, was bilateral at the time of the second stroke, and has continued progressing. It is the background process within which the strokes occurred.

2023 — Aneurysm Treatment

Pipeline Flex embolization of the right cavernous ICA aneurysm, May 2023. Successful — no residual aneurysm filling on subsequent imaging.

2024 Onward — Systemic Escalation

Following a significant dysbiosis event in late 2023, the clinical picture escalated across multiple systems simultaneously. RA activity converted from episodic flares to continuous baseline inflammatory state. Structural joint destruction accelerated markedly — no rheumatoid nodules and no finger deformity were present at the start of 2024; by early 2026, large nodules and deformity across multiple fingers on both hands had developed, with MRI evidence of severe progressive foot and ankle destruction. A mast cell activation pattern emerged for the first time, including chronic urticaria and related manifestations. The simultaneous multi-system escalation across previously stable domains is consistent with a shared upstream driver rather than independent deterioration across separate conditions.

The 2024 dysbiosis escalation specifically increased CNS toxic load through multiple simultaneous channels: LPS crossing a blood-brain barrier more permeable than classical models assumed; inflammatory cytokines with direct CNS effects independent of systemic inflammation; disrupted production of gut-derived neuroactive compounds; and increased oxidative stress reaching CNS tissue directly. The gut collapse was not a parallel stressor — it was a direct neurological insult delivered through mechanisms that bypass rather than respect the blood-brain barrier, hitting the most compromised system at its weakest point.

The 2024 event did not simply accelerate existing disease. It destabilized regulatory capacity that had been holding other systems in check, and those systems expressed vulnerabilities that had been subclinical. Endogenous compensatory processes eventually modulated some of the acute manifestations, but compensation is reallocation of already depleted regulatory resources, not resolution.

July 2025 — Confirmed Structural CNS Damage

The July 2025 MRI with contrast confirmed permanent structural tissue loss — encephalomalacia — in the right insula posteriorly, corresponding to the 2018 infarct site. This is documented, permanent damage to the primary CNS site of autonomic integration, confirmed seven years after the event. The small vessel disease was again noted as slightly increased from the 2018 comparison — confirming ongoing progression.

The insular damage has downstream consequences that extend beyond autonomic regulation. The right insula participates in HPA axis modulation through its connections to hypothalamic regulatory pathways. A flattened diurnal cortisol rhythm — absent classic morning stiffness pattern, now managed with physiologic low-dose hydrocortisone replacement — is consistent with CNS-origin HPA dysregulation as a contributing factor, alongside the broader central regulatory failure picture documented in this section.

II. The Neurological System as the Integrating Territory

The evidence, reviewed across the full chronological picture, consistently points to the neurological system as the primary and integrating territory where the two constitutional factors converge — not merely one affected system among many, but the system whose compromise explains the severity, refractoriness, and breadth of the entire clinical picture.

Neurological Vulnerability Predates Every Formal Diagnosis

The pregabalin episodes, occurring before the RA diagnosis and before any biologic exposure, are the earliest documented expression of a nervous system operating with reduced reserve. The methotrexate reaction — psychiatric in character as much as neurological, unprecedented in both its severity and its rapid resolution — indicates a system that was already close to a threshold the drug crossed within days of the first dose. The consistent pattern across mechanistically unrelated drugs over more than a decade reflects not a series of individual drug sensitivities but a constitutionally compromised nervous system responding predictably to pharmacological perturbation.

This vulnerability has two distinct sources that converge on the same system. The first is developmental — established before any autoimmune disease was identifiable, through early microbiome disruption and autonomic developmental impairment, as described in Section IV. The second is acquired — progressive CNS vascular damage from the autoimmune vasculopathy operating subclinically before it became visible on imaging. Both were present simultaneously from early adulthood. Each amplified the consequences of the other.

The Strokes Are Not the Origin

The strokes are the most visible expression of the neurological picture, but they are not its origin. The small vessel disease was already present at the first stroke imaging in 2016. The unexplained left hand motor impairment documented in 2017 — inconsistent with the left temporal stroke, present a full year before the right insular event — suggests right hemisphere dysfunction that was already developing before the 2018 stroke declared itself on imaging. The bilateral distribution of white matter disease at the time of the second stroke confirms a diffuse process independent of either infarct location. The neurological process was subclinical before it was visible, operating across a system already compromised by developmental vulnerability before the vascular damage began layering onto it.

Central Autonomic Regulation as the Critical Failure Point

The most consequential neurological damage is to central autonomic regulation. The right insular stroke directly damaged the primary CNS site of autonomic integration — confirmed as permanent structural tissue loss on the July 2025 MRI. Combined with the developmental vagal tone deficits documented in the Vagal Tone Deficit reference document — early antibiotic exposure, ACE-related autonomic impairment, pernicious anemia demyelination, chronic inflammatory reflex fatigue — the insular damage represents the final layering of a cumulative deficit that has been reducing the nervous system’s capacity to regulate systemic inflammation throughout the patient’s adult life.

The other dimension of this failure point is the gut-barrier-immune axis. Intestinal barrier dysfunction provides continuous LPS translocation into systemic circulation. This is the engine the compromised autonomic regulation can no longer brake. The two failures are coupled. The result is a system running at inflammatory capacity with its primary regulatory mechanism operating at a fraction of normal output.

The neurological compromise is the mechanism through which the constitutional factors have driven the severity and refractoriness of the entire autoimmune picture. The progressive reduction of regulatory capacity — through developmental impairment first, vascular damage second, and further stressed by the 2024 dysbiosis escalation — allowed the inflammatory picture to escalate beyond what the underlying disease alone would have produced.

III. The Autoimmune Vasculopathy Hypothesis

The evidence points toward a primary autoimmune vasculopathy as the acquired constitutional factor — a condition in which the immune system generates chronic inflammatory and thrombotic activity expressed through vascular tissue, producing progressive damage across multiple vascular territories. What follows is the most specific characterization the available evidence supports, followed by the candidate mechanistic explanations and the one that earns primary focus.

What the Vascular Evidence Establishes

The vascular system is constitutionally abnormal — and this was true at the first available imaging, before surveillance had any opportunity to document change. The persistent right trigeminal artery, already ectatic at first imaging, indicates incomplete vascular developmental regression. The diminutive vertebrobasilar system, present at baseline and unchanged across a decade of imaging, indicates a posterior circulation that never developed its normal architecture. Two intracranial aneurysms were present at first imaging; one grew substantially before treatment, the other has remained stable. A third vascular variant — prominent left posterior communicating artery infundibulum — appeared in later imaging. The constitutional vascular developmental difference is distributed, not focal.

Chronic autoimmune inflammatory activity — confirmed through decades of elevated RF, anti-CCP, persistently elevated IgA, thrombocytosis, and multi-system autoimmune diagnoses — provides the endothelial inflammatory environment in which vessel wall degradation, aneurysm formation, and thrombotic risk operate. The right ICA aneurysm grew most rapidly during the period of worst inflammatory activity and least treatment.

Candidate Mechanistic Explanations

Four mechanistic hypotheses have been identified as candidates for what is producing this vascular and neurological picture. They are not mutually exclusive.

Antiphospholipid syndrome. Autoimmune antibodies directed at phospholipid-binding proteins produce a prothrombotic and vasculopathic state. APS causes cryptogenic stroke, small vessel CNS disease, neurological symptoms preceding thrombotic events by years, and thrombocytosis. Two elevated antiphospholipid antibodies on a single unconfirmed draw, in the context of two cryptogenic strokes, decades of thrombocytosis, and genetic susceptibility signals at STAT4 and HLA loci, constitute substantial circumstantial evidence. Seropositive RA itself carries an approximately 28% prevalence of antiphospholipid antibodies, placing this finding in a population already at elevated baseline risk. APS may be primary or secondary to another autoimmune condition.

Primary autoimmune neurological condition. CNS vasculitis or autoimmune encephalopathy can produce progressive neurological vulnerability, cognitive effects, pain sensitization, and stroke-like events without always generating dramatic presentations that trigger investigation. Specific antibody panels associated with these conditions have not been ordered.

Mitochondrial disease. Multi-system involvement, neurological drug sensitivity, fatigue disproportionate to inflammatory markers, and the SOD2 genetic variant reducing mitochondrial antioxidant capacity are consistent with a mitochondrial vulnerability that has never been formally evaluated. No mitochondrial workup has been performed.

Small vessel CNS disease from chronic inflammatory load. Decades of LPS translocation across a compromised gut barrier, chronic autoimmune inflammatory activity, and possible hypercoagulability have subjected cerebral small vessels to sustained inflammatory and thrombotic stress. The imaging series now confirms this process has been operating continuously since at least 2016, with bilateral distribution at the time of the second stroke confirming diffuse rather than focal involvement.

Focus: Antiphospholipid Syndrome as the Leading Hypothesis

Antiphospholipid syndrome earns primary focus for three reasons.

First, consistency with the available evidence. Two cryptogenic strokes with no cardiac embolic source identified despite comprehensive workup including TEE with bubble study, two elevated antiphospholipid antibodies, decades of thrombocytosis, homozygous platelet hyperactivatability, constitutional vascular abnormalities including aneurysms and a fetal vascular remnant, familial palmar erythema, and documented progressive bilateral small vessel CNS disease predating both strokes — taken together, these describe a vascular system under chronic autoimmune thrombotic and inflammatory stress.

Second, testability. Confirmatory antiphospholipid antibody testing and JAK2 V617F testing both require only a blood draw.

Third, consequence if confirmed. Confirmed APS changes stroke risk management, potentially requires anticoagulation, and reframes the entire treatment history.

The other candidates remain live hypotheses, not dismissed — deferred pending the more immediately testable APS evaluation.

IV. Constitutional and Developmental Context

The clinical picture did not emerge from a neutral baseline. The conditions described in this document developed in a system that was constitutionally shaped — by family inheritance, by early environmental exposures, by developmental disruptions during critical windows — before any diagnosable disease appeared. This section describes that terrain. It does not explain the constitutional condition causally, but it provides the context without which the severity and breadth of the clinical picture is difficult to account for.

Family Pattern

The paternal family line shows a clustering of vascular and autoimmune findings that suggests a heritable constitutional tendency. Multiple paternal siblings share palmar erythema — abnormal capillary dilation indicating dysregulated vascular tone. One paternal brother had rheumatoid arthritis; a same-generation brother has a recurring verbal and motor tic disorder, uninvestigated and undiagnosed. The maternal line contributes its own autoimmune clustering: sisters with celiac disease and RA, a mother with multiple strokes and colon cancer.

The mother’s stroke burden is worth noting in more detail. Multiple strokes accumulated over the final 8-10 years of her life. She had swallowing difficulty requiring postural compensation — habitually positioning her head far back to swallow medications. One fall event during this period had a mechanism worth noting: leaning back to swallow, she continued falling and did not recover postural tone, resulting in a hip fracture. This mechanism — sudden failure to recover postural tone rather than a simple balance failure — is consistent with the postural tone episodes documented in this patient’s own history (pregabalin-induced negative myoclonus) and with the broader autonomic vulnerability picture in the maternal line. It is noted here as a possible heritable signal, not a confirmed finding.

The paternal brothers were raised in East Texas in continuous proximity to petrochemical refineries. The father’s anosmia to refinery chemicals — a marker of lifelong adaptation — indicates chronic exposure beginning in childhood. Petrochemical environments produce documented autoimmune disease induction, vascular endothelial damage, hematological effects including abnormal platelet function, and epigenetic modifications that can persist across generations. Whether the family’s vascular and autoimmune clustering reflects heritable genetic tendency, transgenerational epigenetic effects, or both is not resolvable from available evidence. The clustering itself is the data point.

Genetic Context

Genetic analysis to date is partial — a 23andMe dataset analyzed through Promethease, with a fresh analysis pending. What has been identified is consistent with constitutional susceptibility across the systems implicated in this document, rather than explaining it.

Two independent genetic signals point toward autoimmune vascular susceptibility: STAT4 G/T heterozygosity, associated specifically with antiphospholipid syndrome alongside RA and lupus-like conditions, and homozygous T/T at an HLA-region locus associated with APS and lupus-related autoimmunity. Homozygous ITGB3 PlA2 indicates constitutional platelet hyperactivatability. Homozygous SOD2 A/A reduces mitochondrial antioxidant enzyme import efficiency. Heterozygous GSTP1 A/G reduces glutathione-based detoxification capacity. Homozygous MTHFR A1298C impairs methylation enzyme function. HLA-B27 carrier status raises an unresolved question about spondyloarthropathy contribution to the rheumatological picture.

These variants are not individually diagnostic. Together they describe a system with constitutional vulnerabilities across vascular, immune, mitochondrial, and detoxification pathways.

Family genetic data across approximately three generations and 8-10 family members is available through 23andMe and Ancestry platforms. Comparative Promethease analysis is planned, targeting the variants identified above alongside vascular connective tissue genes not yet assessed.

Early Life Disruptions

Two early life exposures established conditions that shaped the subsequent clinical picture before any autoimmune disease was identifiable.

Continuous antibiotic exposure from infancy through age 7 for recurrent ear infections depleted the gut microbiome during the critical developmental window for autonomic nervous system maturation and mucosal immune tolerance. The consequences — impaired vagal afferent signaling, reduced development of regulatory immune capacity, early dysbiosis establishing conditions for subsequent barrier dysfunction — are developed in the Vagal Tone Deficit reference document. They are noted here as constitutional context: the autonomic nervous system that would later be further compromised by strokes and inflammatory fatigue was already developing on a depleted foundation.

A high Adverse Childhood Experiences score produced structural changes in autonomic nervous system development during sensitive periods — measurable, persistent reductions in parasympathetic tone and heart rate variability that are only partially reversible. Sympathetic dominance established in childhood compounds every subsequent reduction in vagal anti-inflammatory capacity.

These early disruptions shaped the terrain on which it expressed itself — reducing the system’s resilience and amplifying the consequences of the autoimmune and vascular processes that followed.

V. The Broader System

The vasculopathy, if that’s what it is, operates in conjunction with another major system that this document has not explored in detail: a gut-barrier-immune axis driving continuous LPS translocation and systemic inflammatory amplification. The microbiome itself remains pathologically dysbiotic and appears locked in an attractor state that current interventions have not resolved. Helminthic therapy partially restored immune regulation between 2020 and 2023 before losing efficacy following the 2024 dysbiosis event. That collapse appears to have contributed to a nutrient depletion pattern across mitochondrial and barrier-relevant pathways, further compounding the inflammatory and neurological burden. These systems are developed in separate reference documents and are not elaborated here.

The neurological system is the upstream integrating point that ties these tracks to the constitutional picture described in this document. The vagal tone deficit — documented in the Vagal Tone Deficit reference as a five-factor cumulative deficit spanning the lifespan — is both a consequence of the constitutional factors and the mechanism through which they amplify the broader systemic picture. CNS vascular damage reduced the central autonomic regulatory capacity that would otherwise have modulated the inflammatory response driven by the gut-barrier-immune axis.

The collection of separate diagnoses named in the thesis are layered. The gut-barrier-immune dysfunction provides the continuous inflammatory drive. The two converging constitutional factors — developmental neurological vulnerability and autoimmune vasculopathy — removed the primary brake on that drive. The individual diagnoses are the visible surface of a system operating without adequate regulatory capacity at multiple levels simultaneously.

 

Integrated Constitutional Systems Model:
This document reflects current systems-level interpretation, mechanistic analysis, and working hypotheses based on documented history, longitudinal patterns, imaging, laboratory findings, and current research.
It is a thinking and synthesis tool, not a clinical record or formal medical conclusion.

Cross-References

The following documents are part of the master reference system and should be read alongside this document:

This document reflects mechanistic relationships and personal hypotheses based on documented history and current research. It is a thinking tool, not a clinical record. 20260520

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.